We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Siemens Healthineers - Laboratory Diagnostics

Provides advanced laboratory diagnostics solutions for the medical industry read more Featured Products: More products

Download Mobile App




ABL Signs Know-How License and Transfer Agreement for Siemens’ Fast Track Diagnostics PCR Portfolio

By LabMedica International staff writers
Posted on 13 Feb 2025

Advanced Biological Laboratories (ABL, Luxembourg Ville, Luxembourg) has signed a licensing and transfer agreement with Siemens Healthineers (Forchheim, Germany) for the know-how and IP rights from Fast Track Diagnostics Luxembourg (FTD). More...

FTD was engaged in developing, manufacturing, and selling in-vitro diagnostic and research using only molecular testing products. As the owner of FTD, Siemens has licensed and transferred the know-how and IP rights to ABL and its affiliates (ABL Group) related to the design and manufacturing of certain former FTD products. Based on this Know-How License and Transfer Agreement (Agreement), the ABL group intends to manufacture and commercialize its testing products equivalent to the former FTD products. The licensed know-how is related to real-time Polymerase Chain Reaction (PCR) tests, allowing for both singleplex and syndromic testing, to target conditions such as respiratory infections, gastroenteritis, meningitis, hepatitis, infections of the immunosuppressed, tropical diseases, sexually transmitted diseases, and early childhood diseases, and detect over 100 viruses, bacteria, parasites, and fungi.

Unlike a clinical examination alone, it can distinguish between viral, bacterial, or other infections in one test. By integrating new PCR tests based on FTD know-how and IP rights to its molecular diagnostics portfolio, ABL Group is further investing in precision medicine and better patient experience through solutions that eliminate the need for repeat diagnostic testing, reducing time and improving patient outcomes. The Agreement expands the ABL Group molecular diagnostics portfolio with a potential of up to 38 products to be manufactured within the ABL UltraGene family. ABL intends to develop a combined strategy of reflex testing from these new products and the DeepChek products for genotyping sequencing. This will further expand ABL’s footprint in infectious diseases by being a global supplier of standalone software, detection tests, and genotyping by sequencing tests. The expanded ABL portfolio, tests, and syndromic panels, can help transform care delivery for its customers with a comprehensive solution for molecular testing of infectious diseases. In addition, ABL's platform-agnostic menu allows ABL Group to effectively serve a broader customer base.

"By integrating the high-quality of the know-how developed by Fast Track Diagnostics into our own cutting-edge molecular diagnostics portfolio, ABL continues to strengthen and expand its presence in the field of molecular testing and precision medicine," said Dr. Chalom B. Sayada, CEO and Founder, Advanced Biological Laboratories. "It means great things for all of our customers globally and delivers better outcomes for their patients."

"We are excited to manufacture our new ABL UltraGene products using FTD’s know-how and IP rights and to integrate them into our compliance plan to the European regulation for in-vitro diagnostics medical devices (2017/746, IVDR)," added Ronan Boulmé, GRC Director for the ABL Group.


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Serological Pipet Controller
PIPETBOY GENIUS
New
Mini Vortex Mixer
Vornado
New
cDNA Synthesis Kit
Ultimate cDNA Synthesis Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: Microscopy image of invasive breast cancer cells degrading their underlying extracellular matrix (Photo courtesy of University of Turku)

Visualization Tool Illuminates Breast Cancer Cell Migration to Suggest New Treatment Avenues

Patients with breast cancer who progress from ductal carcinoma in situ (DCIS) to invasive ductal carcinoma (IDC) face a significantly worse prognosis, as metastatic disease remains incurable.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.